KemPharm, Inc. (KMPH) financial statements (2021 and earlier)

Company profile

Business Address 1180 CELEBRATION BOULEVARD, SUITE 103
CELEBRATION, FL 34747
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4322426851
Cash and cash equivalents4318111732
Short-term investments  3315119
Restricted cash and investments0  11 
Receivables320252
Prepaid expense000000
Capitalized contract cost 1 
Deferred costs10    
Other undisclosed current assets002100
Total current assets:8724477454
Noncurrent Assets
Operating lease, right-of-use asset12
Property, plant and equipment112220
Long-term investments and receivables   38 
Long-term investments   38 
Regulated entity, other noncurrent assets     1
Restricted cash and investments 01   
Other noncurrent assets011000
Total noncurrent assets:3435112
TOTAL ASSETS:111127528556
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:758865
Accounts payable114201
Accrued liabilities111111
Employee-related liabilities101111
Interest and dividends payable102221
Other undisclosed accounts payable and accrued liabilities231221
Debt004403
Other liabilities00000 
Other undisclosed current liabilities0     
Total current liabilities:85121278
Noncurrent Liabilities
Long-term debt and lease obligation707979909120
Long-term debt, excluding current maturities687778899120
Capital lease obligations01  
Operating lease, liability22
Liabilities, other than long-term debt00111 
Other liabilities00111 
Other undisclosed noncurrent liabilities0028538
Total noncurrent liabilities:708081989758
Total liabilities:78859311010466
Stockholders' equity
Stockholders' equity attributable to parent(66)(74)(67)(58)(19)(10)
Common stock 00000
Additional paid in capital19217115510710395
Accumulated deficit(258)(246)(221)(165)(121)(105)
Total stockholders' equity:(66)(74)(67)(58)(19)(10)
TOTAL LIABILITIES AND EQUITY:111127528556

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues1313    
Cost of revenue(1)(10)    
Cost of goods and services sold (10)    
Gross profit:123    
Operating expenses(18)(30)(56)(33)(37)(23)
Other undisclosed operating income 7    
Operating loss:(6)(20)(56)(33)(37)(23)
Nonoperating income (expense)(7)(4)(1)(10)21(32)
Interest and debt expense(5)(5)0(6)(5)(3)
Loss from continuing operations before equity method investments, income taxes:(18)(29)(57)(49)(21)(57)
Other undisclosed income (loss) from continuing operations before income taxes55(0)653
Loss from continuing operations before income taxes:(13)(25)(57)(43)(17)(55)
Income tax expense (benefit)00000(0)
Net loss available to common stockholders, diluted:(13)(25)(56)(43)(17)(55)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(13)(25)(56)(43)(17)(55)
Comprehensive loss, net of tax, attributable to parent:(13)(25)(56)(43)(17)(55)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: